Do Fast Track Regulatory Pathways Mean Quicker Reimbursement For Gene Therapies?
Executive Summary
The norms on securing market access are being rewritten for cell and gene therapies.
You may also be interested in...
How Novartis Is Tailoring Its Strategy In Asia Pacific, Middle East and Africa
Iris Zemzoum, Novartis Pharma's president for Asia Pacific, Middle East and Africa, outlines how the company is shaping its strategy in the region, which comes with “extremes” in market profiles, via a distinct archetype that factors in commonalities between national healthcare systems. The company is also progressing interesting initiatives in digital therapeutics.
Confronting The Challenges Of Marketing Cell And Gene Therapies
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.